Literature DB >> 29582548

Haemoglobin A1c variability is a strong, independent predictor of all-cause mortality in patients with type 2 diabetes.

Emanuela Orsi1, Anna Solini2, Enzo Bonora3, Cecilia Fondelli4, Roberto Trevisan5, Monica Vedovato6, Franco Cavalot7, Gabriella Gruden8, Susanna Morano9, Antonio Nicolucci10, Giuseppe Penno11, Giuseppe Pugliese12.   

Abstract

AIMS: To evaluate various measures of haemoglobin (Hb) A1c variability, compared with average HbA1c, as independent predictors of mortality.
MATERIALS AND METHODS: The Renal Insufficiency And Cardiovascular Events Italian multicentre study enroled 15 733 patients with type 2 diabetes from 19 diabetes clinics during 2006-2008. A total of 3 to 5 HbA1c measures, obtained during the 2-year period before enrolment, were available from 9 centres (8290 patients) and were used to calculate average HbA1c (HbA1c -MEAN) and HbA1c variability, measured as intra-individual standard deviation (HbA1c-SD), SD adjusted for the number of HbA1c assessments (HbA1c-AdjSD) and coefficient of variation (HbA1c-CV), that is, the HbA1c-SD to HbA1c-MEAN ratio. Vital status on October 31, 2015 was retrieved for 8252 patients (99.5%).
RESULTS: The measures of HbA1c variability increased according to quartiles of HbA1c-MEAN and vice versa. HbA1c-MEAN and measures of HbA1c variability were associated with all-cause mortality; however, the strength of association of HbA1c-MEAN was lower than that of HbA1c -SD, HbA1c-CV or HbA1c-AdjSD, and disappeared after adjusting for confounders and any of the measures of HbA1c variability. Mortality increased with quartiles of HbA1c-MEAN, HbA1c -SD, HbA1c-CV and HbA1c-AdjSD, but only the association with HbA1c variability measures remained after adjustment for confounders and/or each other measure. In the fully adjusted model, mortality risk was lower for HbA1c-SD below the median and higher for HbA1c-SD above the median, regardless of whether HbA1c-MEAN was below or above the median. Conclusions HbA1c variability is a strong, independent predictor of all-cause mortality in type 2 diabetes and appears to be even more powerful than average HbA1c in predicting mortality.
© 2018 John Wiley & Sons Ltd.

Entities:  

Keywords:  HbA1c; all-cause mortality; cardiovascular risk factors; complications; type 2 diabetes; variability

Mesh:

Substances:

Year:  2018        PMID: 29582548     DOI: 10.1111/dom.13306

Source DB:  PubMed          Journal:  Diabetes Obes Metab        ISSN: 1462-8902            Impact factor:   6.577


  17 in total

1.  Association between visit-to-visit variability of HbA1c and cognitive decline: a pooled analysis of two prospective population-based cohorts.

Authors:  Zhe-Bin Yu; Yao Zhu; Die Li; Meng-Yin Wu; Meng-Ling Tang; Jian-Bing Wang; Kun Chen
Journal:  Diabetologia       Date:  2019-09-04       Impact factor: 10.122

2.  Glucose-Lowering Agents and the Risk of Hypoglycemia: a Real-world Study.

Authors:  Beini Lyu; Y Joseph Hwang; Elizabeth Selvin; Brian C Jameson; Alex R Chang; Morgan E Grams; Jung-Im Shin
Journal:  J Gen Intern Med       Date:  2022-07-13       Impact factor: 6.473

Review 3.  Glycemic variability: adverse clinical outcomes and how to improve it?

Authors:  Zheng Zhou; Bao Sun; Shiqiong Huang; Chunsheng Zhu; Meng Bian
Journal:  Cardiovasc Diabetol       Date:  2020-07-04       Impact factor: 9.951

4.  Renal hyperfiltration is independently associated with increased all-cause mortality in individuals with type 2 diabetes: a prospective cohort study.

Authors:  Giuseppe Penno; Emanuela Orsi; Anna Solini; Enzo Bonora; Cecilia Fondelli; Roberto Trevisan; Monica Vedovato; Franco Cavalot; Gabriella Gruden; Luigi Laviola; Antonio Nicolucci; Giuseppe Pugliese
Journal:  BMJ Open Diabetes Res Care       Date:  2020-07

5.  Comparative predictive ability of visit-to-visit HbA1c variability measures for microvascular disease risk in type 2 diabetes.

Authors:  Chen-Yi Yang; Pei-Fang Su; Jo-Ying Hung; Huang-Tz Ou; Shihchen Kuo
Journal:  Cardiovasc Diabetol       Date:  2020-07-06       Impact factor: 9.951

6.  Phenotyping individuals with newly-diagnosed type 2 diabetes at risk for all-cause mortality: a single centre observational, prospective study.

Authors:  Edoardo Biancalana; Federico Parolini; Alessandro Mengozzi; Anna Solini
Journal:  Diabetol Metab Syndr       Date:  2020-05-25       Impact factor: 3.320

7.  Fasting glucose variability in young adulthood and incident diabetes, cardiovascular disease and all-cause mortality.

Authors:  Michael P Bancks; April P Carson; Cora E Lewis; Erica P Gunderson; Jared P Reis; Pamela J Schreiner; Yuichiro Yano; Mercedes R Carnethon
Journal:  Diabetologia       Date:  2019-05-22       Impact factor: 10.122

8.  Association between On-Treatment Haemoglobin A1c and All-Cause Mortality in Individuals with Type 2 Diabetes: Importance of Personalized Goals and Type of Anti-Hyperglycaemic Treatment.

Authors:  Emanuela Orsi; Enzo Bonora; Anna Solini; Cecilia Fondelli; Roberto Trevisan; Monica Vedovato; Franco Cavalot; Gianpaolo Zerbini; Susanna Morano; Antonio Nicolucci; Giuseppe Penno; Giuseppe Pugliese
Journal:  J Clin Med       Date:  2020-01-17       Impact factor: 4.241

9.  Visit-to-visit variability of glycemia and vascular complications: the Hoorn Diabetes Care System cohort.

Authors:  Roderick C Slieker; Amber A W H van der Heijden; Giel Nijpels; Petra J M Elders; Leen M 't Hart; Joline W J Beulens
Journal:  Cardiovasc Diabetol       Date:  2019-12-12       Impact factor: 9.951

10.  Mean and variability of annual haemoglobin A1c are associated with high-risk peripheral artery disease.

Authors:  I-Te Lee
Journal:  Diab Vasc Dis Res       Date:  2020 Mar-Apr       Impact factor: 3.291

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.